Does Hepatitis C treatment put you at risk for Hepatitis B reactivation?

The U.S, Food and Drug Administration (FDA) has issued a warning to patients getting treated for hepatitis C. According to this prominent,”boxed” warning, they are at a risk for reactivation of hepatitis B virus.

However, one needs to ascertain the following facts for a better understanding of the risks:

  1. The warning applies to patients with a history of hep B but the risk factor can be inferred by whether the infection is active, dormant or resolved.
  2. In case of HBV and HCV coinfected patients, it is presumed that both the viruses keep each other under control. But once hep C is cured, the viral load and liver enzymes may increase and symptoms of hep B like fatigue and jaundice surfaces.
  3. Patients with the history of hepatitis B need to be tested for HBsAg (hepatitis B surface antigen), anti-HBs (antibodies to the HBV surface antigen) and anti-HBc (antibodies to the HBV core antigen) before starting their HCV treatment.

We are here to help! Save more than 70% of your medical bill! Get helpful information about managing Hep C.


There is no apparent risk for people who are HBsAg negative and anti-Hbc and anti-HBc positive.

4.If HBsAg is positive, then a hepatitis B viral load test should be done before, during and immediately after hep C treatment.Though at a very low risk of reactivation, people who have resolved HBV infection, need periodical monitoring during their hep C treatment.

5.Those prone to hepatitis B need to get vaccinated.

According to FDA, there were 24 confirmed cases of reactivation in HBV/HCV coinfected patients treated with DAAs between November 2013 and July 2016.Two died, one needed liver transplant and three experienced hepatic decomposition. Half the patients received hep B treatment and most of them showed a decrease in HBV DNA.
The FDA confirmed that HBV reactivation usually occurred within 4 to 8 weeks after starting treatment with DAA and was visible in people with detectable and undetectable HBV DNA at baseline.


Surcation® is already helping patients whose insurance doesn’t cover the cost of Harvoni® with medical tourism. If you chose the similar treatment in the US, it costs between $84,000 and $95,000 just for the medication. If you are approved by your insurance, you still have today’s high deductibles and co-pays. You pay just $6800 when you chose hepatitis medical tourism with Surcation®. You can bring your spouse along for a total price is $6,400. Our clients are offered the best treatment available provided by world renowned doctors at a fraction of the cost. Surcation® offers medical financing if needed.


Call 928-328-8909 to get helpful information, a Hep C guide, and facts about managing Hep C.

Get Your Tourism package
Surcation is a trademark of Destination Surcations, LLC. All other trademarks are the property of their respective owners.
Web Design Credits